16:14 EDT Jasper Therapeutics (JSPR) files $300M mixed securities shelf
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics
- Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones
- Positive Outlook on Jasper Therapeutics: Sustained Efficacy and Safety of Briquilimab in CSU Treatment
- Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments
- Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue